Company type | Public |
---|---|
TSX: ACB Nasdaq: ACB | |
Industry | Cannabis |
Founded | 2006 |
Founders | Terry Booth, Steve Dobler, Chris Mayerson, Dale Lesack |
Headquarters | , |
Area served | Canada, Europe, Australia |
Key people | Miguel Martin (CEO) |
Revenue | Can$176 million (March 2023)[1] |
Can$ -158 million (2023)[1] | |
Can$ -208 million (2023)[1] | |
Total assets | Can$484 million (2023)[1] |
Total equity | Can$491 million (2023)[1] |
Number of employees | 1130 |
Subsidiaries | Pedanios GmbH, Urban Cultivator, Australis Capital Inc., CanvasRx Inc., H2 Biopharma Inc., Peloton Pharmaceuticals Inc., Aurora Larssen Projects Ltd., Larssen Ltd., Aurora Cannabis Enterprises Inc., BC Northern Lights Enterprises Ltd., Medreleaf (Australia) |
Website | www |
Aurora Cannabis Inc. is a Canadian licensed cannabis producer, headquartered in Edmonton. It trades on the Toronto Stock Exchange and Nasdaq as ACB.[2] As of September 2018[update], Aurora Cannabis had eight licensed production facilities, five sales licences, and operations in 25 countries.[3] It had a funded capacity of over 625,000 kilograms of cannabis production per annum with the bulk of capacity based in Canada and a growing presence in international markets, particularly Denmark and Latin America.[4] The company began trading on the NYSE on October 23, 2018, using the ticker ACB.[5][6]
After significant expansion in 2018, the company reduced expenses in the second half of 2019 when the Canadian recreational cannabis market had low sales due to excessive inventory and uncompetitive pricing with the black market.[7] In February 2020, cofounder and chief executive, Terry Booth, resigned, being replaced by Executive Chairman Michael Singer as interim CEO.[8]